MANKIND2,246.00

Mankind Pharma Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersSUNPHARMACIPLATORNTPHARMLAURUSLABSBIOCONALKEMLUPINGLENMARKMcap ₹92,715 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations10,334.812,207.414,277.614,737.9
Other Income280.9536.8358.8323.9
Total Income10,615.612,744.214,636.415,061.8
Expenses
+ Cost of Materials Consumed1,853.52,016.42,288.02,387.2
+ Purchases of Stock-in-Trade1,409.91,655.71,728.01,870.3
+ Changes in Inventories-53.7-183.036.1-160.7
+ Employee Benefit Expense2,274.72,692.43,183.93,314.0
+ Finance Costs33.5429.4639.3578.6
+ Depreciation & Amortisation398.3621.2886.2893.2
+ Other Expenses2,315.33,008.13,424.23,500.3
Total Expenses8,231.510,240.112,185.712,382.9
EBITDA2,535.13,017.93,617.43,826.8
EBIT2,136.82,396.72,731.22,933.6
Profit
PBT before Exceptional Items2,384.12,504.12,450.72,678.9
+ Exceptional Items0.00.0-129.8-129.8
Pretax Income2,384.12,504.12,321.02,549.2
+ Current Tax492.6596.0582.9682.6
+ Deferred Tax-35.0-86.3-188.3-188.5
Tax Expense457.6509.7394.6494.1
+ Share of Associates & JVs15.212.211.712.5
Net Income1,941.82,011.11,938.12,067.6
+ Net Income — Continuing Ops1,926.61,994.41,926.42,055.1
+ Net Income — Discontinued Ops0.04.50.00.0
+ Other Comprehensive Income-8.0-8.357.037.5
Total Comprehensive Income1,933.82,002.81,995.12,105.1
Net Income to Common1,912.91,986.41,912.9
Minority Interest28.920.225.2
Per Share
Basic EPS47.7549.2846.3549.49
Diluted EPS47.6849.1946.2849.42
Continuing & Discontinued Operations
+ Discontinued Operations — before Tax0.08.50.00.0
+ Tax — Discontinued Operations0.03.90.00.0
Other Comprehensive Income — detail
+ Other Comprehensive Income-8.357.037.5
+ Items NOT to be Reclassified to P&L-9.7-5.631.931.2
+ Tax on Items NOT to be Reclassified-3.56.25.7
+ Tax on Items NOT to be Reclassified — alt tag-3.6
+ Items to be Reclassified to P&L-2.0-6.231.311.9
Comprehensive Income — Owners of Parent1,904.71,982.856.6
Comprehensive Income — Non-controlling Interests29.120.00.5
Per Share — as-filed variants
Basic EPS — Continuing Operations47.7549.1746.3549.49
Diluted EPS — Continuing Operations47.6849.0846.2849.42
Basic EPS — Discontinued Operations0.000.110.000.00
Diluted EPS — Discontinued Operations0.000.110.000.00
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit7,125.18,718.410,225.510,641.1
Gross Margin %68.9471.4271.6272.20
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)2,384.12,504.12,450.72,678.9
− Exceptional Items (reconciliation)0.00.0-129.8-129.8
Net Income Adj (tax-effected)1,941.82,011.12,045.82,172.2
EPS Adj47.7549.2848.9351.99
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value1.001.001.001.00
Filed Debt Equity0.010.000.00
Filed Dscr0.010.000.01
Filed Iscr1.310.040.09
Paid Up Equity Capital40.141.341.341.3
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.